Stereotactic Body Radiotherapy (SBRT) in Very Limited-Stage Small Cell Lung Cancer (VLS-SCLC)

• Published in: Current oncology (Toronto) 2022-12, Vol.30 (1), p.100-109
• Main Authors: Mercier, Stéphanie L, Moore, Sara M, Akurang, Deborah, Tiberi, David, Wheatley-Price, Paul
• Format: Article
• Language: English
• Subjects: Humans; limited stage; Lung Neoplasms - drug therapy; Lung Neoplasms - radiotherapy; Lung Neoplasms - surgery; Neoplasm Recurrence, Local - surgery; Radiosurgery; SABR; SBRT; SCLC; Small Cell Lung Carcinoma - drug therapy; Small Cell Lung Carcinoma - radiotherapy; Small Cell Lung Carcinoma - surgery; Treatment Outcome
• ISSN: 1718-7729; 1198-0052; 1718-7729
• DOI: 10.3390/curroncol30010008

Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumour with metastatic propensity. Stereotactic body radiation therapy (SBRT) is an emerging therapeutic option for SCLC, despite limited supporting evidence. By evaluating the use of SBRT in very limited stage (VLS) SCLC at our institution, we aimed to contribute to the existing knowledge in this area while establishing a basis for further research. We performed a retrospective review of all cases of VLS-SCLC treated with SBRT between 2013 and 2020. Baseline demographics, diagnostic, and treatment information were collected. The primary outcome was overall survival (OS). We identified 46 patients with pathologically confirmed VLS-SCLC; 25 were treated with SBRT, and the remainder received either surgery, conventional radiation therapy, chemotherapy, or palliative-intent therapy. After a median follow-up of 23.7 months, 44% of the patients had died; the median OS was of 24.4 months for the SBRT cohort and 67.0 months for the curative intent non-SBRT cohort. The difference in disease recurrence and survival between cohorts was underpowered and not statistically significant. Higher baseline ECOG and comorbidity was noted in the SBRT cohort.